The use of ‘in-built’, molecularly defined adjuvants such as non-coding RNA may also augment the capacity of immune cells to orchestrate a potent anti-tumor immune responses in vivo, e.g. by activating the RNA sensing molecule retinoic acid-inducible gene I (RIG-1) (128). Here, RIGI is linked to neoplasm.